Agios Pharmaceuticals (AGIO) Non-Current Assets (2012 - 2026)

Agios Pharmaceuticals has reported Non-Current Assets for 15 years, with the latest figure at $350.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 40.34% year-over-year to $350.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (down 29.55% YoY), and the FY2025 full-year result was $355.2 million, down 49.09% from the prior year.
• Non-Current Assets for Q1 2026 stood at $350.1 million, down from $355.2 million in the prior quarter.
• The five-year high for Non-Current Assets was $717.6 million in Q3 2024, with the low at $103.3 million in Q4 2023.
• Historically, Non-Current Assets has averaged $381.0 million across 5 years, with a median of $359.6 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 74.56% — and 2024, when it soared 575.42%.
• Agios Pharmaceuticals' Non-Current Assets stood at $405.9 million in 2022, then tumbled by 74.56% to $103.3 million in 2023, then soared by 575.42% to $697.6 million in 2024, then sank by 49.09% to $355.2 million in 2025, then dropped by 1.42% to $350.1 million in 2026.
• The last three Non-Current Assets figures came in at $350.1 million (Q1 2026), $355.2 million (Q4 2025), and $352.6 million (Q3 2025), per Business Quant data.